Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 2, 2013, Pages 253-260

  Warkentin, T E ^a   Sheppard, J I ^a   Sun, J C J ^b   Jung, H ^c   Eikelboom, J W ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Antibody; Fondaparinux; Heparin; Postcoronary artery bypass surgery; Thrombosis; Venous graft occlusion

Indexed keywords

FONDAPARINUX; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG CROSS REACTIVITY; ENZYME IMMUNOASSAY; GRAFT OCCLUSION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SEROTONIN RELEASE; THROMBOSIS PREVENTION; VEIN GRAFT DISEASE; VENOUS GRAFT OCCLUSION;

ANTIBODIES; ANTICOAGULANTS; CORONARY ARTERY BYPASS; CROSS REACTIONS; GRAFT OCCLUSION, VASCULAR; HEPARIN; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; LOGISTIC MODELS; ODDS RATIO; ONTARIO; PILOT PROJECTS; PLATELET FACTOR 4; POLYSACCHARIDES; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873559762     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12098     Document Type: Article

References (20)

1. Gluckman TJ, Segal JB, Schulman SP, Shapiro EP, Kickler TS, Prechel MM, Conte JV, Walenga JM, Shafique I, Rade JJ. Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost 2009; 7: 1457-64.
2. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128: 837-41.
3. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-6.
4. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4: 281-2.
5. Sun JCJ, Teoh KHT, Sheth T, Landry D, Jung H, Warkentin TE, Yusuf S, Lamy A, Eikelboom JW. Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. J Thromb Thrombolysis 2011; 32: 378-85.
6. Krakow EF, Goudar R, Petzold E, Suvarna S, Last M, Welsby IJ, Ortel TL, Arepally GM. Influence of sample collection and storage on the detection of platelet factor 4-heparin antibodies. Am J Clin Pathol 2007; 128: 150-5.
7. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
8. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996; 95: 161-7.
9. Warkentin TE, Cook RJ, Marder VJ, Sheppard JI, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-6.
10. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998; 80: 292-7.
11. Pouplard C, Couvret C, Regina S, Gruel Y. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005; 3: 2813-5.
12. Warkentin TE, Davidson BL, Büller HR, Gallus A, Gent M, Lensing AWA, Piovella F, Prins MH, Segers AEM, Kelton JG. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140: 366-73.
13. Parang P, Arora R. Coronary vein graft disease: pathogenesis and prevention. Can J Cardiol 2009; 25: e57-62.
14. Kowalska MA, Krishnaswamy S, Rauova L, Zhai L, Hayes V, Amirikian K, Esko JD, Bougie DW, Aster RH, Cines DB, Poncz M. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Blood 2011; 118: 2882-8.
15. Sperry JL, Deming CB, Bian C, Walinsky PL, Kass DA, Kolodgie FD, Virmani R, Kim AY, Rade JJ. Wall tension is a potent negative regulator of in vivo thrombomodulin expression. Circ Res 2003; 92: 41-7.
16. Lentz SR. Thrombosis of vein grafts. Wall tension restrains thrombomodulin expression. Circ Res 2003; 92: 12-3.
17. Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, Seligsohn U. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009; 7: 1070-4.
18. Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9: 2498-500.
19. Paparella D, Scrascia G, Galeone A, Coviello M, Cappabianca G, Venneri MT, Favoino B, Quaranta M, de Luca Tupputi Schinosa L, Warkentin TE. Formation of anti-platelet factor 4/heparin antibodies following cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J Thorac Cardiovasc Surg 2008; 136: 1456-63.
20. Selleng S, Malowsky B, Ittermann T, Bagemühl J, Wessel A, Wollert HG, Warkentin TE, Greinacher A. Incidence and clinical relevance of anti-PF4/heparin antibodies before cardiac surgery. Am Heart J 2010; 160: 362-9.